[go: up one dir, main page]

IL321165A - Vanglustat in combination with a strong or moderate CYP3A4 inhibitor - Google Patents

Vanglustat in combination with a strong or moderate CYP3A4 inhibitor

Info

Publication number
IL321165A
IL321165A IL321165A IL32116525A IL321165A IL 321165 A IL321165 A IL 321165A IL 321165 A IL321165 A IL 321165A IL 32116525 A IL32116525 A IL 32116525A IL 321165 A IL321165 A IL 321165A
Authority
IL
Israel
Prior art keywords
venglustat
cyp3a4
strong
combination
moderate inhibitor
Prior art date
Application number
IL321165A
Other languages
English (en)
Hebrew (he)
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of IL321165A publication Critical patent/IL321165A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
IL321165A 2022-12-01 2023-11-30 Vanglustat in combination with a strong or moderate CYP3A4 inhibitor IL321165A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263429338P 2022-12-01 2022-12-01
PCT/IB2023/062098 WO2024116127A1 (fr) 2022-12-01 2023-11-30 Venglustat en combinaison avec un inhibiteur fort ou modéré de cyp3a4

Publications (1)

Publication Number Publication Date
IL321165A true IL321165A (en) 2025-07-01

Family

ID=89168110

Family Applications (1)

Application Number Title Priority Date Filing Date
IL321165A IL321165A (en) 2022-12-01 2023-11-30 Vanglustat in combination with a strong or moderate CYP3A4 inhibitor

Country Status (9)

Country Link
EP (1) EP4626424A1 (fr)
JP (1) JP2025541739A (fr)
KR (1) KR20250106321A (fr)
CN (1) CN120417900A (fr)
AU (1) AU2023403087A1 (fr)
IL (1) IL321165A (fr)
MX (1) MX2025006345A (fr)
TW (1) TW202430159A (fr)
WO (1) WO2024116127A1 (fr)

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE640616A (fr) 1962-12-19
US3492397A (en) 1967-04-07 1970-01-27 Warner Lambert Pharmaceutical Sustained release dosage in the pellet form and process thereof
US4060598A (en) 1967-06-28 1977-11-29 Boehringer Mannheim G.M.B.H. Tablets coated with aqueous resin dispersions
US3538214A (en) 1969-04-22 1970-11-03 Merck & Co Inc Controlled release medicinal tablets
US4173626A (en) 1978-12-11 1979-11-06 Merck & Co., Inc. Sustained release indomethacin
US4683195A (en) 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
TWI634119B (zh) 2011-03-18 2018-09-01 美商健臻公司 葡萄糖神經醯胺合成酶抑制劑
JOP20130273B1 (ar) 2012-09-11 2021-08-17 Genzyme Corp مثبطات انزيم (سينثاز) غلوكوسيل سيراميد
JO3713B1 (ar) 2013-03-15 2021-01-31 Genzyme Corp أشكال ملح (s)-كوينوكليدين-3-يل(2-(2-(4-فلوروفينيل)ثيازول-4-يل)بروبان-2-يل)كارباميت
TW201642855A (zh) 2015-03-10 2016-12-16 健臻公司 用於治療蛋白質病變之方法
WO2020163337A1 (fr) 2019-02-04 2020-08-13 Genzyme Corporation Traitement de ciliopathies à l'aide d'inhibiteurs de la glucosylcéramide synthase (gcs)
CN211869663U (zh) 2019-09-27 2020-11-06 唐旭明 一种船用侧推进器连接结构
MX2023001014A (es) 2020-07-24 2023-03-01 Genzyme Corp Composiciones farmaceuticas que comprenden venglustat.

Also Published As

Publication number Publication date
MX2025006345A (es) 2025-07-01
AU2023403087A1 (en) 2025-07-17
CN120417900A (zh) 2025-08-01
WO2024116127A1 (fr) 2024-06-06
KR20250106321A (ko) 2025-07-09
JP2025541739A (ja) 2025-12-23
EP4626424A1 (fr) 2025-10-08
TW202430159A (zh) 2024-08-01

Similar Documents

Publication Publication Date Title
EP4349838A4 (fr) Inhibiteur de wee1 et son utilisation
IL323738A (en) Prmt5 inhibitors and their uses
PT2015754E (pt) Utilizações de inibidores da dpp iv
EP4186894A4 (fr) Composé inhibiteur de fgfr et son utilisation
EP4378938A4 (fr) Nouvel inhibiteur de parp7 et son utilisation
EP4582427A4 (fr) Inhibiteur d'usp1
GB202008201D0 (en) Inhibitor compounds
GB202004960D0 (en) Inhibitor compounds
IL321165A (en) Vanglustat in combination with a strong or moderate CYP3A4 inhibitor
GB202219537D0 (en) Corrosion inhibitor
EP4338737A4 (fr) Inhibiteur de parp7 et son utilisation
CA3275143A1 (fr) Venglustat en combinaison avec un inhibiteur fort ou modéré de cyp3a4
EP4226919A4 (fr) Inhibiteur de la ferroptose
IL207816A0 (en) Mmp-2 and/or mmp-9 inhibitor
GB201916563D0 (en) Corrosion inhibitor
EP4561975A4 (fr) Inhibiteurs de fto
IL316710A (en) Flavivirus inhibitors
CA204362S (en) Floating table
IL176771A0 (en) Combination of voriconazole and an antifungal cyp2c19 inhibitor
GB202110373D0 (en) Inhibitor compounds
EP4545087A4 (fr) Inhibiteur de sénescence
ZA202202522B (en) Fto inhibitor zinc202913277 and application thereof
HK40100193B (zh) Lpa抑制剂及其用途
HK40100193A (zh) Lpa抑制剂及其用途
GB202004636D0 (en) Enzyme inhibitor